News for Arcutis Biotherapeutics, Inc. (ARQT)

**media[553498]**

Arcutis Biotherapeutics Inc (ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced on February 28, 2025, that it wil

One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intoler

Strengths highlight Arcutis' advanced product pipeline and commercialization of ZORYVE.Weaknesses underscore the company's financial losses and reliance on ZOR

Arcutis Biotherapeutics Inc (ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced on February 26, 2025, that the U.

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025 Application supported by positiv

Release Date: February 25, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Arcutis Biot

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NARQT.OQ - Arcutis Biotherapeutics IncQ4 2024 Arcutis Biotherapeutics Inc Earnings CallFeb 25,

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ETCompany ParticipantsLatha Vairavan - Vice...

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 66.67% and 23.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[550229]**

WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared

Arcutis Biotherapeutics Inc (ARQT) is set to release its Q4 2024 earnings on Feb 25, 2025. The consensus estimate for Q4 2024 revenue is $0.06 billion, and the

WESTLAKE VILLAGE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ( ARQT), a commercial-stage biopharmaceutical company focused on dev

**media[543776]**

The consensus price target hints at a 51.6% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Arcutis Biotherapeutics (ARQT) rose 12% amid some takeover speculation.

Arcutis Biotherapeutics (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.